ImmunoPrecise Antibodies Ltd. Overview
Pro stress-test →ImmunoPrecise Antibodies is an innovation-driven, technology platform company that supports pharmaceutical and biotechnology company partners in discovering and developing novel therapeutic antibodies. The company reported Fiscal Year 2025 revenue of $24.5 million CAD with a gross margin of 55%, driven by its AI-powered BioStrand segment which grew over 180%. IPA is leveraging its proprietary LENSai™ platform to pioneer AI-designed assets and secure major partnerships, including a recent $8M-$10M USD deal for co-developing next-generation biotherapeutics.
Strategic Profile
Pro stress-test →IPA is transforming the conventional, multivendor product development model by bringing innovative, high-throughput, data-driven discovery services to its partners. The company evolved from a traditional profitable Canadian custom antibody service provider founded in 1983 to an AI-driven drug discovery firm centered on its LENSai platform, with acceleration occurring after its 2016 public listing and strategic acquisitions like BioStrand BV in 2021. In addition to CRO services, IPA's wholly-owned subsidiary Talem Therapeutics offers R&D to support internally-owned and partnered therapeutic asset development.
Competitive Landscape
Pro stress-test →IPA has over 30 years of experience in the custom antibody business, completing roughly 4,000 projects for hundreds of clients globally, including a majority of the top 20 largest pharmaceutical companies. Competitors include traditional antibody discovery CROs (Abcam, Charles River), emerging AI-driven drug discovery platforms, and internal antibody programs at large pharma. IPA's differentiation lies in integrating proprietary AI technologies (LENSai, BioStrand) with deep domain expertise and global infrastructure.
Industry Context
ImmunoPrecise Antibodies Ltd. operates in AI-driven therapeutic antibody discovery.
Key facts
Founded: 1983 · Headquarters: Victoria, Canada · Employees: 51-100 · Revenue: $24.5M CAD (FY2025) · Market cap: N/A